EMA Recommends Extension of Indications for Sugemalimab By Ogkologos - October 28, 2025 121 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer MOST POPULAR Improved Survival Benefit with Encorafenib plus Cetuximab plus mFOLFOX6 in First-Line... June 25, 2025 Ibrutinib-Containing Immunochemotherapy in Front-Line Treatment of Young, Medically Fit Patients with... May 14, 2024 The ecDNA story – catching the mastermind behind cancer evolution February 20, 2023 New Treatment Helps Survivors Regain Sensation After Breast Cancer October 21, 2020 Load more HOT NEWS 2022 ASCO Annual Meeting: A New Targeted Therapy Combination for Low-Grade Brain... A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical... Working to Raise Prostate Cancer Awareness: A Patient Advocate’s Story 18-Year-Old Jaguar at Akron Zoo Diagnosed with Breast Cancer
